Summary
Quest Diagnostics Incorporated (DGX) has filed an 8-K report on November 29, 2001, detailing the completion of its previously announced public offering of $250 million in 1.75% contingent convertible debentures due 2021, which occurred on November 26, 2001. This offering represents a significant financing event for the company, providing capital for its operations and strategic initiatives. The filing also includes an exhibit, specifically the opinion of Shearman & Sterling dated November 26, 2001, regarding certain tax matters related to this debenture offering. While the operational details or financial performance related to this issuance are not elaborated upon in this specific 8-K, the successful completion of a large debt offering suggests management's confidence in the company's financial health and its ability to service the new debt.
Key Highlights
- 1Quest Diagnostics successfully completed a $250 million public offering of 1.75% contingent convertible debentures due 2021 on November 26, 2001.
- 2The debentures have a maturity date of 2021.
- 3The offering's coupon rate is 1.75%.
- 4The company secured a legal opinion from Shearman & Sterling regarding certain tax matters related to the debenture offering.
- 5This filing marks the formal announcement of the closing of this significant debt financing.
- 6The 8-K was filed on November 29, 2001, reporting an event on November 26, 2001.